newsfilter
← Latest News
GlobeNewswire·

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

  • BriaCell Therapeutics presented positive preclinical data on its Bria-OTS+ platform at the 2026 AACR Annual Meeting in San Diego.
  • The Bria-OTS+ platform is a personalized, off-the-shelf, next-generation genetically engineered whole-cell cancer immunotherapy designed to enhance efficacy & safety.
  • In vitro models demonstrated that Bria-OTS+ activates both innate & adaptive immunity, including CD4+ T cells, CD8+ T cells, NK cells, NKT cells, dendritic cells, & B cells.
  • The platform exhibits serial killing activity across multiple rounds of tumor cell challenge without functional exhaustion of immune cells.
  • Bria-BRES+ (breast cancer) & Bria-PROS+ (prostate cancer) variants drove rapid immune response activation & increased cytotoxic activity against parental tumor targets.
  • Bria-OTS+ showed limited induction of immunosuppressive cell populations such as regulatory T cells (Tregs) & myeloid-derived suppressor cells (MDSCs).
  • The proposed mechanism involves intradermal administration to activate T cells & NK cells directly while antigen-presenting cells prime tumor-specific T cells in lymph nodes.
  • The company plans to advance Bria-OTS+ into clinical trials for metastatic breast cancer & prostate cancer later in 2026.
  • Additional clinical indications for lung cancer & melanoma are planned for 2027.